/ /

ModernMedicine Resource Center More Topics

Hepatology Resource Center

Researchers: Hepatitis C virus control needs a public health approachA new study suggests a public health approach is necessary to control the spread of hepatitis C virus in urban communities.
DAAs safely treat chronic kidney disease in HCV patientsDirect-acting antiviral therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney disease.
DAAs improve patient and graft survival after liver transplantLiver transplant outcomes have improved following the introduction of new hepatitis C virus drugs, according to a new study.
Primary care can manage hep C infections with DAAsPrimary care professionals can “substantially expand” HCV treatment in the community, according to new research.
Report highlights critical actions needed to monitor HCV epidemicA new report highlights key missing elements needed to achieve complete elimination of hepatitis C virus.
Direct-acting antivirals reduce liver cancer riskA sustained response to direct-acting antivirals lowers the risk of hepatocellular carcinoma, a new study finds.
Direct-acting antivirals prevent liver cancer recurrenceNew research finds direct-acting antivirals can be given safely to those on liver transplant waitlist.
Sofosbuvir reduces transplant rate in HCV patientsSofosbuvir-based therapy successfully treats HCV patients with decompensated liver disease, according to a new study.
Triple directing-acting combination treats decompensated liver diseaseA combination of three drugs successfully treats HCV-infected patients with advanced liver disease.
Liver transplant recipients with HCV fare well under drug comboHepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.